- Home
- NAAS vs PTN Comparison
NAAS vs PTN Comparison
Compare NAAS & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- PTN
- Stock Information
- Founded
- NAAS 2019
- PTN 1986
- Country
- NAAS China
- PTN United States
- Employees
- NAAS N/A
- PTN N/A
- Industry
- NAAS Other Specialty Stores
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- NAAS Consumer Discretionary
- PTN Health Care
- Exchange
- NAAS Nasdaq
- PTN Nasdaq
- Market Cap
- NAAS 18.9M
- PTN 20.9M
- IPO Year
- NAAS 2017
- PTN 1993
- Fundamental
- Price
- NAAS $0.70
- PTN $0.54
- Analyst Decision
- NAAS
- PTN Strong Buy
- Analyst Count
- NAAS 0
- PTN 1
- Target Price
- NAAS N/A
- PTN $7.00
- AVG Volume (30 Days)
- NAAS 1.4M
- PTN 904.9K
- Earning Date
- NAAS 05-08-2025
- PTN 05-14-2025
- Dividend Yield
- NAAS N/A
- PTN N/A
- EPS Growth
- NAAS N/A
- PTN N/A
- EPS
- NAAS N/A
- PTN N/A
- Revenue
- NAAS $43,258,393.00
- PTN $350,000.00
- Revenue This Year
- NAAS $19.53
- PTN N/A
- Revenue Next Year
- NAAS $151.36
- PTN N/A
- P/E Ratio
- NAAS N/A
- PTN N/A
- Revenue Growth
- NAAS 50.34
- PTN N/A
- 52 Week Low
- NAAS $0.66
- PTN $0.46
- 52 Week High
- NAAS $23.40
- PTN $2.88
- Technical
- Relative Strength Index (RSI)
- NAAS 29.92
- PTN 28.90
- Support Level
- NAAS $0.66
- PTN $0.68
- Resistance Level
- NAAS $0.73
- PTN $0.84
- Average True Range (ATR)
- NAAS 0.08
- PTN 0.08
- MACD
- NAAS -0.00
- PTN -0.02
- Stochastic Oscillator
- NAAS 7.74
- PTN 20.22
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.